Medova, Michaela

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2010 | 2009 | 2008

2020

Dommann, Noëlle; Sánchez Taltavull, Daniel; Eggs, Linda; Birrer, Fabienne Esther; Brodie, Tess; Salm, Lilian; Baier, Felix Alexander; Medova, Michaela; Humbert, Magali; Tschan, Mario; Beldi, Guido; Candinas, Daniel; Stroka, Deborah (2020). The LIM Protein Ajuba Augments Tumor Metastasis in Colon Cancer. Cancers, 12(7) MDPI AG 10.3390/cancers12071913

Bensimon, Ariel; Koch, Jonas P.; Francica, Paola; Roth, Selina M.; Riedo, Rahel; Glück, Astrid A.; Orlando, Eleonora; Blaukat, Andree; Aebersold, Daniel M.; Zimmer, Yitzhak; Aebersold, Ruedi; Medová, Michaela (2020). Deciphering MET-dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomics. Molecular oncology, 14(6), pp. 1185-1206. Elsevier 10.1002/1878-0261.12696

Koch, Jonas P.; Aebersold, Daniel M.; Zimmer, Yitzhak; Medová, Michaela (2020). MET targeting: time for a rematch. Oncogene, 39(14), pp. 2845-2862. Springer Nature 10.1038/s41388-020-1193-8

Nisa, Lluís; Francica, Paola; Giger, Roland; Medo, Matúš; Eliçin, Olgun; Friese-Hamim, Manja; Wilm, Claudia; Stroh, Christopher; Bojaxhiu, Beat; Quintin, Aurélie; Caversaccio, Marco D.; Dettmer, Matthias S.; Buchwalder, Mélanie; Brodie, Tess M.; Aebersold, Daniel M.; Zimmer, Yitzhak; Carey, Thomas E.; Medova, Michaela (2020). Targeting the MET receptor tyrosine kinase as a strategy for radiosensitization in loco-regionally advanced head and neck squamous cell carcinoma. Molecular cancer therapeutics, 19(2), pp. 614-626. American Association for Cancer Research AACR 10.1158/1535-7163.MCT-18-1274

Zimmer, Yitzhak; Reinhardt, Hans Christian; Medová, Michaela (2020). Editorial: Exploiting DNA Damage Response in the Era of Precision Oncology. Frontiers in oncology, 10 Frontiers Research Foundation 10.3389/fonc.2020.611127

2019

Medo, Matúš; Aebersold, Daniel M.; Medova, Michaela (2019). ProtRank: bypassing the imputation of missing values in differential expression analysis of proteomic data. BMC bioinformatics, 20(1), p. 563. BioMed Central 10.1186/s12859-019-3144-3

Gavini, Jacopo; Dommann, Noëlle; Jakob, Manuel O.; Keogh, Adrian; Bouchez, Laure C; Karkampouna, Sofia; Kruithof-de Julio, Marianna; Medova, Michaela; Zimmer, Yitzhak; Schläfli, Anna M; Tschan, Mario P.; Candinas, Daniel; Stroka, Deborah; Banz, Vanessa (2019). Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma. Cell death & disease, 10(10), p. 749. Springer Nature 10.1038/s41419-019-1989-z

Poliaková, Michaela; Felser, Andrea; Pierzchala, Katarzyna; Nuoffer, Jean-Marc; Aebersold, Daniel; Zimmer, Yitzhak; Zamboni, Nicola; Medova, Michaela (2019). Metabolomics reveals tepotinib-related mitochondrial dysfunction in MET activating mutations-driven models. FEBS journal, 286(14), pp. 2692-2710. Wiley-Blackwell 10.1111/febs.14852

Orlando, Eleonora; Aebersold, Daniel; Medova, Michaela; Zimmer, Yitzhak (2019). Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase. Cancer letters, 443, pp. 189-202. Elsevier 10.1016/j.canlet.2018.12.001

Muñoz-Maldonado, Carmen; Zimmer, Yitzhak; Medova, Michaela (2019). A Comparative Analysis of Individual RAS Mutations in Cancer Biology. Frontiers in oncology, 9, p. 1088. Frontiers Research Foundation 10.3389/fonc.2019.01088

2018

Nisa, Lluís; Barras, David; Medova, Michaela; Aebersold, Daniel M.; Medo, Matúš; Poliaková, Michaela; Koch, Jonas; Bojaxhiu, Beat; Eliçin, Olgun; Dettmer, Matthias S.; Angelino, Paolo; Giger, Roland; Borner, Urs; Caversaccio, Marco D.; Carey, Thomas E; Ho, Liza; McKee, Thomas A; Delorenzi, Mauro; Zimmer, Yitzhak (2018). Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease. Molecular cancer research, 16(12), pp. 1912-1926. American Association for Cancer Research AACR 10.1158/1541-7786.MCR-18-0056

Glück, Astrid Andreina; Orlando, Eleonora; Leiser, Dominic; Poliakova, Michaela; Nisa Hernández, Lluís; Quintin, Aurelie; Gavini, Jacopo; Keogh-Stroka, Deborah M.; Berezowska, Sabina; Bubendorf, Lukas; Blaukat, Andree; Aebersold, Daniel; Medova, Michaela; Zimmer, Yitzhak (2018). Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxia. Oncogene, 37(30), pp. 4181-4196. Nature Publishing Group 10.1038/s41388-018-0256-6

Brodie, Tess; Tosevski, Vinko; Medova, Michaela (2018). OMIP-045: Characterizing human head and neck tumors and cancer cell lines with mass cytometry. Cytometry Part A, 93(4), pp. 406-410. Wiley 10.1002/cyto.a.23336

Poliakova, Michaela; Aebersold, Daniel; Zimmer, Yitzhak; Medova, Michaela (2018). The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer. Molecular cancer, 17(1), p. 27. BioMed Central 10.1186/s12943-018-0798-9

Melin, Nicolas; Fahrner, René; Keogh, Adrian; Medova, Michaela; Zimmer, Yitzhak; Aebersold, Daniel; Candinas, Daniel; Beldi, Guido; Keogh-Stroka, Deborah M. (2018). Direct and indirect hepatoprotective mechanism of CBLB502 a TLR5 agonist. Journal of hepatology, 68, S140-S141. Elsevier 10.1016/S0168-8278(18)30497-5

2017

Nisa Hernández, Lluís; Häfliger, Pascal; Poliakova, Michaela; Giger, Roland; Francica, Paola; Aebersold, Daniel; Charles, Roch-Philippe; Zimmer, Yitzhak; Medova, Michaela (2017). PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models. Molecular cancer, 16(1), p. 93. BioMed Central 10.1186/s12943-017-0660-5

Nita, Izabela Magdalena; Hostettler, Katrin; Tamò, Luca Giuseppe Athos; Medova, Michaela; Bombaci, Giuseppe; Zhong, Jun; Allam, Ramanjaneyulu; Zimmer, Yitzhak; Roth, Michael; Geiser, Thomas; Gazdhar, Amiq (2017). Hepatocyte growth factor secreted by bone marrow stem cell reduce ER stress and improves repair in alveolar epithelial II cells. Scientific Reports, 7(41901), p. 41901. Nature Publishing Group 10.1038/srep41901

Francica, Paola; Aebersold, Daniel; Medova, Michaela (2017). Senescence as biologic endpoint following pharmacological targeting of receptor tyrosine kinases in cancer. Biochemical pharmacology, 126, pp. 1-12. Elsevier 10.1016/j.bcp.2016.08.022

2016

Francica, Paola; Nisa Hernandez, Lluis; Aebersold, Daniel; Langer, Rupert; Bladt, Friedhelm; Blaukat, Andree; Keogh-Stroka, Deborah M.; Martínez, María Rodríguez; Zimmer, Yitzhak; Medova, Michaela (2016). Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer. Clinical cancer research, 22(21), pp. 5322-5336. American Association for Cancer Research 10.1158/1078-0432.CCR-15-2987

Medova, Michaela (2016). Tepotinib. Selective MET receptor tyrosine kinase inhibitor, Treatment of lung and liver cancers. Drugs of the Future, 41(11), p. 659. Prous Science 10.1358/dof.2016.041.11.2555984

2015

Mikami, K.; Medova, Michaela; Nisa Hernandez, Lluis; Francica, Paola; Glück, Astrid Andreina; Tschan, Mario; Blaukat, A.; Bladt, F.; Aebersold, Daniel; Zimmer, Yitzhak (2015). Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation. Molecular cancer research, 13(12), pp. 1544-1553. American Association for Cancer Research AACR 10.1158/1541-7786.MCR-15-0022

Leiser, Dominic; Medova, Michaela; Mikami, Kei; Nisa Hernandez, Lluis; Keogh-Stroka, Deborah M.; Blaukat, Andree; Bladt, Friedhelm; Aebersold, Daniel; Zimmer, Yitzhak (2015). KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells. Molecular oncology, 9(7), pp. 1434-1446. Elsevier 10.1016/j.molonc.2015.04.001

Piguet, Anne-Christine; Medova, Michaela; Keogh, Adrian; Glück, Astrid Andreina; Aebersold, Daniel; Dufour, Jean-François; Dufour, Jean-François; Zimmer, Yitzhak (2015). Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer. Genes & cancer, 6(7-8), pp. 317-327. Impact Journals

Glück, Astrid Andreina; Aebersold, Daniel; Zimmer, Yitzhak; Medova, Michaela (2015). Interplay between receptor tyrosine kinases and hypoxia signaling in cancer. The international journal of biochemistry & cell biology, 62, pp. 101-114. 10.1016/j.biocel.2015.02.018

Nisa Hernandez, Lluis; Aebersold, Daniel; Giger, Roland; Caversaccio, Marco; Borner, Urs; Medova, Michaela; Zimmer, Yitzhak (2015). Profiling invasiveness in head and neck cancer: recent contributions of genomic and transcriptomic approaches. Cancers, 7(2), pp. 585-597. MDPI AG 10.3390/cancers7020585

2014

Nisa Hernandez, Lluis; Aebersold, Daniel; Giger, Roland; Zimmer, Yitzhak; Medova, Michaela (2014). Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer. Pharmacology & therapeutics, 143(3), pp. 337-349. Elsevier 10.1016/j.pharmthera.2014.04.005

Leiser, Dominic; Pochon, Benoît; Blank Wieslawa, Elzbieta; Francica, Paola; Glück, Astrid; Aebersold, Daniel; Zimmer, Yitzhak; Medova, Michaela (2014). Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation. FEBS letters, 588(5), pp. 653-658. Elsevier 10.1016/j.febslet.2013.12.025

Medova, Michaela; Aebersold, Daniel M.; Zimmer, Yitzhak (2014). The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response - Biological and Clinical Aspects. Cancers, 6(1), pp. 1-27. MDPI AG 10.3390/cancers6010001

2013

Medová, Michaela; Pochon, Benoît; Streit, Bruno; Blank-Liss, Wieslawa; Francica, Paola; Stroka, Deborah; Keogh, Adrian; Aebersold, Daniel M.; Blaukat, Andree; Bladt, Friedhelm; Zimmer, Yitzhak (2013). The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants. Molecular cancer therapeutics, 12(11), pp. 2415-2424. American Association for Cancer Research AACR 10.1158/1535-7163.MCT-13-0151

Humbert, Magali; Medova, Michaela; Aebersold, Daniel; Blaukat, Andree; Bladt, Friedhelm; Fey, Martin; Zimmer, Yitzhak; Tschan, Mario P. (2013). Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells. Biochemical and biophysical research communications, 431(2), pp. 264-269. Academic Press 10.1016/j.bbrc.2012.12.120

2012

Medová, Michaela; Aebersold, Daniel M; Zimmer, Yitzhak (2012). MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks. International journal of cancer, 130(3), pp. 728-34. Malden, Mass.: Wiley-Blackwell 10.1002/ijc.26058

2010

Zimmer, Yitzhak; Vaseva, Angelina V; Medová, Michaela; Streit, Bruno; Blank-Liss, Wieslawa; Greiner, Richard H; Schiering, Nikolaus; Aebersold, Daniel M (2010). Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274. Cancer letters, 289(2), pp. 228-36. Amsterdam: Elsevier 10.1016/j.canlet.2009.08.017

2009

Banz, Vanessa M; Medová, Michaela; Keogh, Adrian; Furer, Cynthia; Zimmer, Yitzhak; Candinas, Daniel; Stroka, Deborah (2009). Hsp90 transcriptionally and post-translationally regulates the expression of NDRG1 and maintains the stability of its modifying kinase GSK3beta. Biochimica et biophysica acta - molecular cell research, 1793(10), pp. 1597-603. New York, N.Y.: Elsevier 10.1016/j.bbamcr.2009.08.002

2008

Ganapathipillai, Suganthini S; Medová, Michaela; Aebersold, Daniel M; Manley, Paul W; Berthou, Sylvie; Streit, Bruno; Blank-Liss, Wieslawa; Greiner, Richard H; Rothen-Rutishauser, Barbara; Zimmer, Yitzhak (2008). Coupling of mutated Met variants to DNA repair via Abl and Rad51. Cancer research, 68(14), pp. 5769-77. Birmingham, Ala.: American Association for Cancer Research AACR 10.1158/0008-5472.CAN-08-1269

Provide Feedback